Hideo Shigematsu

Dr. Hideo Shigematsu

Breast surgery, Hiroshima University, Hiroshima, Japan
orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 February 2020 in Supportive Care in Cancer
Verified
Journal Article
Open access
PDF file
HSHideo Shigematsu
Hideo Shigematsu
THTaizo Hirata
Taizo Hirata
MNMai Nishina
Mai Nishina
DYDaisuke Yasui
Daisuke Yasui
SOShinji Ozaki
Shinji Ozaki
Purpose: This randomized phase II study was conducted to investigate the efficacy of cryotherapy in preventing peripheral neuropathy and dermatological adverse events in breast cancer patients treated with weekly paclitaxel. Methods: Patients treated with 12 weekly doses of paclitaxel for breast cancer were randomized (1:1) into a cryotherapy or control group. The primary endpoint was the percentage of patients with a marked decrease in the Functional Assessment of Cancer Therapy-Neurotoxicity (FACT-NTX) score. The secondary endpoints were Patient Neurotoxicity Questionnaire (PNQ), Common Terminology Criteria for Adverse Event (CTCAE) for peripheral neuropathy, and FACT-Taxane score. Results: Forty-four patients were randomly assigned to the cryotherapy (n = 22) or control groups (n = 22). The percentage of patients with a marked decrease in FACT-NTX scores was significantly lower in the cryotherapy group than in the control group (41 vs. 73%, p = 0.03). The incidence of CTCAE grade ≥ 2 sensory (p = 0.001) and motor peripheral neuropathy (p = 0.01), and PNQ grade D or higher for sensory peripheral neuropathy (p = 0.02), and decrease in the FACT-Taxane score (p = 0.02) were also significantly lower in the cryotherapy group than in the control group. There were no serious side effects associated with cryotherapy. Conclusion: Cryotherapy is an effective approach for prevention of peripheral neuropathy and dermatological adverse events in breast cancer patients treated with weekly paclitaxel.

1 February 2018 in Clinical Breast Cancer
Verified
Journal Article
Closed access
EAEtsushi Akimoto
Etsushi Akimoto
TKTakayuki Kadoya
Takayuki Kadoya
KKKeiko Kajitani
Keiko Kajitani
AEAkiko Emi
Akiko Emi
HSHideo Shigematsu
Hideo Shigematsu
MOMorihito Okada
Morihito Okada

5 December 2014 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
HSHideo Shigematsu
Hideo Shigematsu
KTKenichi Taguchi
Kenichi Taguchi
HKHiroko Koui
Hiroko Koui
SOShinji Ohno
Shinji Ohno

1 June 2018 in Oncotarget
Verified
Journal Article
Open access
PDF file
HSHideo Shigematsu
Hideo Shigematsu
SOShinji Ozaki
Shinji Ozaki
DYDaisuke Yasui
Daisuke Yasui
HYHideki Yamamoto
Hideki Yamamoto
JZJunichi Zaitsu
Junichi Zaitsu
KTKiyomi Taniyama
Kiyomi Taniyama
Overexpression of topoisomerase II alpha protein is a factor for poor prognosis in patients with luminal B breast cancer Overexpression of topoisomerase II alpha protein is a factor for poor prognosis in patients with luminal B breast cancer

7 May 2020 in Japanese Journal of Clinical Oncology
Verified
Journal Article
Open access
PDF file
HSHideo Shigematsu
Hideo Shigematsu
TFTomomi Fujisawa
Tomomi Fujisawa
Tadahiko ShienTadahiko Shien
Tadahiko Shien
Hiroji IwataHiroji Iwata
Hiroji Iwata
Breast cancer is highly sensitive to systemic therapy. High probability of pathological complete response suggests a clinical question that omitting surgery is an effective alternative to surgery in breast cancer showing clinical complete response to primary systemic therapy. However, the validity of omitting surgery for early breast cancer after primary systemic therapy has not been sufficiently established; thus, even if pathological complete response is expected in patients showing clinical complete response, excision of the primary tumor site remains the standard treatment of breast cancer. Inappropriate omitting surgery increases the incidence of local recurrence, which can be the risk of a subsequent distant metastasis and reduced overall survival. To achieve acceptable local control rate, omitting surgery should be investigated in patients with early breast cancer where a high percentage of pathological complete response, a high concordance rate between clinical complete response and pathological complete response and an acceptable local control rate are expected. This review presents concept and ongoing clinical trials for omitting surgery for patients with breast cancer showing clinical complete response to primary systemic therapy.

31 March 2011 in BMC Cancer
Verified
Journal Article
Open access
PDF file
HSHideo Shigematsu
Hideo Shigematsu
HKHidetoshi Kawaguchi
Hidetoshi Kawaguchi
YNYoshiaki Nakamura
Yoshiaki Nakamura
KTKimihiro Tanaka
Kimihiro Tanaka
SSSatoko Shiotani
Satoko Shiotani
SOShinji Ohno
Shinji Ohno
It is unclear whether individualized treatments based on biological factors have improved the prognosis of recurrent breast cancer. The purpose of this study is to evaluate the survival improvement of patients with recurrent breast cancer after the introduction of third generation aromatase inhibitors (AIs) and trastuzumab.